Clinical trials: SARS-CoV-2 Infections
COVID-19
A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects
This study will be a single center, Phase I, randomized, double-blind, placebo controlled, single and multiple ascending dose (SAD/MAD) study evaluating the safety, tolerability, and PK of Delcetravir after administration via…
- Trial name
- NCT05453279
- Testing
- Delcetravir dry powder inhaler
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Esfam Biotech Pty Ltd
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
- Trial name
- ASPIRE (NCT04557046)
- Testing
- Nasal Swab, Nasopharyngeal swab, Throat swab
- Where
- 7 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- LumiraDx UK Limited
Multiple Sclerosis
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
- Trial name
- NCT05576779
- Testing
- Ofatunumab
- Where
- United States
- Volunteers
- 2,101 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, SARS-CoV 2
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by…
- Conditions
- COVID-19, SARS-CoV 2, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04456088
- Testing
- 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System
- Sponsor
- Beyond Air Inc.
Covid19
Study of GRAd-COV2 for the Prevention of COVID-19 in Adults
Multicenter Study assessing the safety, efficacy, and immunogenicity of the candidate vaccine GRAd-COV2, compared to placebo, for the prevention of COVID-19.
- Trial name
- COVITAR (NCT04791423)
- Testing
- GRAd-COV2
- Where
- 26 sites in Italy
- Volunteers
- 10,300 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
Acute Lung Injury, ALI
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory…
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Trial name
- NCT04574869
- Testing
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg
- Where
- United States
- Sponsor
- ReAlta Life Sciences, Inc.
SARS-CoV-2 Infection
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
The purpose of this study is to evaluate the safety of STI-1558 in healthy subjects and the safety, pharmacokinetics, and efficacy in SARS-CoV-2-Positive subjects.
- Trial name
- NCT05523739
- Testing
- STI-1558
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on…
- Conditions
- COVID-19, Chronic Bronchitis, Copd
- Trial name
- NCT05075057
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Covid19
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is To evaluate the safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose.
- Trial name
- NCT05067894
- Testing
- SARS-CoV-2 Protein Subunit Recombinant Vaccine, SARS-CoV-2 Inactivated Vaccine
- Where
- Indonesia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Infection
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients
A Nasal Spray device containing Dead Sea minerals and plant extracts, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients
- Trial name
- NCT04974190
- Testing
- Nasal Spray Device
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- The Grasses of Eden Ltd
Covid19
Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects
Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as the comparator method against the Nanomix eLab® system.
- Trial name
- NCT04667442
- Testing
- Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Nanomix
COVID-19
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Trial name
- NCT04603651
- Testing
- Bamlanivimab
- Sponsor
- Eli Lilly and Company
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
Covid19
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
This study investigates the safety, pharmacokinetic (PK) profile and efficacy of a single injection of COVI-AMG in outpatient adults with mild COVID-19 symptoms.
- Trial name
- NCT04734860
- Testing
- COVI-AMG
- Where
- 4 sites in United States
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19 Respiratory Infection
ALACOVID Study for Vaccinated Subjects
In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation…
- Trial name
- COVID-19 (NCT05234346)
- Testing
- 150 mg 5-ALAPhosphate + SFC
- Where
- 4 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
COVID-19
Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)
This is an open-labeled, no placebo, Phase IIa clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of one booster vaccine dose of SARS-CoV-2 DNA Vaccine (ICCOV) in adults aged 18 to 75 years who…
- Trial name
- NCT05904054
- Testing
- SARS-CoV-2 DNA Vaccine (ICCOV)
- Where
- Hong Kong
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Immuno Cure 3 Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.